Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts
Amgen agreed to offer Aimovig and Amjevita at $299 per month through its AmgenNow program, following a U.S. drug-pricing deal tied to the TrumpRx rollout. The agreement includes most-favored-nation pricing and tariff relief. Shares last traded at $327.38. Wall Street remains split on the stock heading into 2026.